The company has received final approval from the Department of Pharmaceuticals, Government of India, for foreign investment under applicable regulations
The amalgamation is expected to create a future-ready, diversified CDMO platform with a technology-led focus across three high-growth verticals-Antibody Drug Conjugates
This acquisition positions Suven as a key player in one of the fastest growing segments of the Pharma CDMO landscape
The company will address these observations within the stipulated timeline
Sapala has a strong customer base including innovator Pharma, CDMOs & diagnostic companies
The Indian pharmaceutical industry is projected to reach US$ 130 billion by 2030
_256_384.jpg)
The overall transaction is expected to conclude over next 12-15 months subject to receipt of all relevant shareholder and regulatory approvals
Suven Pharmaceuticals’ API and forumulations facilities complete USFDA inspection successfully
The aggregate foreign investment, including investment from other foreign investors may be up to 90.1% shareholding in the company
The approval is for acquisition of up to 76.1% equity shares of Suven Pharmaceuticals by Berhyanda Limited
Subscribe To Our Newsletter & Stay Updated
